Literature DB >> 28802566

Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.

Lisa B VanWagner1, Hongyan Ning2, Norrina B Allen2, Veeral Ajmera3, Cora E Lewis4, John Jeffrey Carr5, Donald M Lloyd-Jones6, Norah A Terrault3, Juned Siddique2.   

Abstract

BACKGROUND & AIMS: Cardiovascular disease (CVD) is the leading cause of death among patients with nonalcoholic fatty liver disease (NAFLD). Moderate drinking (vs abstinence) is associated with lower risk of CVD in the general population. We assessed whether alcohol use is associated with CVD risk in patients with NAFLD.
METHODS: We analyzed data from participants in the Coronary Artery Risk Development in Young Adults longitudinal cohort study of 5115 black and white young adults, 18-30 years old, recruited from 4 cities in the United States from 1985 through 1986. Participants self-reported alcohol use at study entry and then again after 15, 20, and 25 years. At year 25 (2010-2011), participants underwent computed tomography examination of the thorax and abdomen and tissue Doppler echocardiography with myocardial strain measured by speckle tracking. Coronary artery calcification was defined as an Agatston score above 0. NAFLD was defined as liver attenuation <51 Hounsfield Units after exclusions. Drinkers reported 1-21 (men) or 1-14 (women) standard drinks/week at years 15, 20, or 25. Nondrinkers reported no alcohol use at years 15, 20, and 25.
RESULTS: Of the 570 participants with NAFLD (mean age, 50 years; 54% black; 46% female), 332 (58%) were drinkers; significantly higher proportions of drinkers were white, male, and with higher levels of education compared with nondrinkers (P < .05 for all). Higher proportions of drinkers had obesity, diabetes, and metabolic syndrome compared with nondrinkers (P < .01). There was no difference in liver attenuation between groups (P = .12). After multivariable adjustment, there was no association between alcohol use and CVD risk factors (diabetes, hypertension, hyperlipidemia) or subclinical CVD measures (coronary artery calcification, early transmitral velocity/late (atrial) transmitral velocity (E/A) ratio, global longitudinal strain).
CONCLUSIONS: In a population-based sample of individuals with NAFLD in midlife, prospectively assessed alcohol use is not associated with significant differences in risk factors for CVD or markers of subclinical CVD. In contrast to general population findings, alcohol use may not reduce the risk of CVD in patients with NAFLD.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CARDIA Study; Heart Disease; NAFLD; NASH

Mesh:

Year:  2017        PMID: 28802566      PMCID: PMC5669829          DOI: 10.1053/j.gastro.2017.08.012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  56 in total

1.  Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT.

Authors:  J J Carr; J R Crouse; D C Goff; R B D'Agostino; N P Peterson; G L Burke
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

2.  Meta-analysis of wine and beer consumption in relation to vascular risk.

Authors:  Augusto Di Castelnuovo; Serenella Rotondo; Licia Iacoviello; Maria Benedetta Donati; Giovanni De Gaetano
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

Review 3.  Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02       Impact factor: 8.311

4.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.

Authors:  E B Rimm; P Williams; K Fosher; M Criqui; M J Stampfer
Journal:  BMJ       Date:  1999-12-11

Review 5.  An update on alcohol and atherosclerosis.

Authors:  Joseph M Li; Kenneth J Mukamal
Journal:  Curr Opin Lipidol       Date:  2004-12       Impact factor: 4.776

6.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

7.  Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study.

Authors:  Craig R Walsh; Martin G Larson; Jane C Evans; Luc Djousse; R Curtis Ellison; Ramachandran S Vasan; Daniel Levy
Journal:  Ann Intern Med       Date:  2002-02-05       Impact factor: 25.391

8.  Alcohol intake is not associated with subclinical coronary atherosclerosis.

Authors:  Jeanne K Tofferi; Allen J Taylor; Irwin M Feuerstein; Patrick G O'Malley
Journal:  Am Heart J       Date:  2004-11       Impact factor: 4.749

9.  Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial.

Authors:  Michael J Davies; David J Baer; Joseph T Judd; Ellen D Brown; William S Campbell; Philip R Taylor
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

10.  Alcohol consumption, coronary calcium, and coronary heart disease events.

Authors:  T Yang; T M Doherty; N D Wong; R C Detrano
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

View more
  18 in total

1.  Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease.

Authors:  James Philip Esteban; Amreen Dinani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-03

2.  Alcohol use in patients with non-alcoholic fatty liver: a tangled web of causality.

Authors:  Danielle Brandman; Norah A Terrault
Journal:  Hepatobiliary Surg Nutr       Date:  2019-06       Impact factor: 7.293

3.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

4.  Magnesium intake is inversely associated with risk of non-alcoholic fatty liver disease among American adults.

Authors:  Liping Lu; Cheng Chen; Yuexia Li; Wenzhi Guo; Shuijun Zhang; John Brockman; James M Shikany; Ka Kahe
Journal:  Eur J Nutr       Date:  2021-11-06       Impact factor: 5.614

Review 5.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

Review 6.  Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease.

Authors:  Rachel L Bachrach; Shari S Rogal
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-23

7.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.

Authors:  Veeral Ajmera; Patricia Belt; Laura A Wilson; Ryan M Gill; Rohit Loomba; David E Kleiner; Brent A Neuschwander-Tetri; Norah Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-14       Impact factor: 11.382

8.  Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease.

Authors:  Michelle T Long; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Timothy S Naimi
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-14       Impact factor: 11.382

9.  Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Authors:  Hersh Shroff; Lisa B VanWagner
Journal:  Curr Hepatol Rep       Date:  2020-06-29

10.  Casual alcohol consumption is associated with less subclinical cardiovascular organ damage in Koreans: a cross-sectional study.

Authors:  Jeonggeun Moon; In Cheol Hwang; Kyoung Kon Kim; Woong Chol Kang; Ji-Young Cha; Young-Ah Moon
Journal:  BMC Public Health       Date:  2018-09-04       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.